Objectives: Studies done on the management of oral lichen planus using tacrolimus are limited. The aim of the study is to compare the efficacy of tacrolimus with triamcinolone acetonide topically in the management of symptomatic oral lichen planus and also to evaluate adverse effects and opportunistic yeast infections.
INTRODUCTION
Lichen planus (LP) is a chronic inflammatory mucocutaneous condition, which most commonly affects the skin, genitalia and oral mucous membranes. The oral lesions are chronic, rarely undergo spontaneous remission, are potentially malignant and often a source of morbidity. In long-standing disease, especially the erosive or atrophic forms, malignant transformation has been reported in 0.4 to 5.6% of cases. 1 
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Oral lichen planus (OLP) affects about 0.1 to 4% of general population. 2 The occurrence was reported from 0.4 to 0.6% of dental patients. 3 Mehta et al found that 0.1 to 1% of OLP were among the rural inhabitants of India, however in one of the districts in Kerala state, authors found that the prevalence is 1.5%. 4 A promising new treatment for OLP is the topical form of the immunosuppressive macrolide tacrolimus. In 1984, the macrolide immunomodulator FK506 was isolated from the fungus Streptomyces tsukubaensis in Japan. 5 The name of the drug tacrolimus is a neologism that is composed of tsukuba, macrolide and immunosuppressant. The discovery of the drug was the result of a search for immunomodulatory agents in the field of organ transplantation. 6 Tacrolimus is available as a systemic (prograf) and a topical (protopic) medication. Very recently, topical tacrolimus (concentrations of 0.1, 0.3 and 0.03%) in orabase has been shown to be effective in the treatment of OLP. This hydrophobic polycyclic lactone has powerful immunosuppressive activities. The molecular mechanism for its anti-inflammatory action is similar to that of cyclosporine, which involves the inhibition of interleukin 2 (IL-2) production by T cells. 5 The aims of our study were:
(i) Comparison of response to treatment with 0.1% tacrolimus orabase (study group) and 0.1% triamcinolone acetonide orabase (control group).
(ii) To evaluate any adverse effects on patients with topical application of 0.1% tacrolimus. (iii) To assess development of opportunistic yeast infections like candidiasis following treatment with both tacrolimus and triamcinolone acetonide.
MATERIALS AND METHODS
This study was planned during the period of January 2008 to June 2009 in the Department of Oral Medicine, SDM College of Dental Sciences, Dharwad, Karnataka, India. Sixty patients suffering from symptomatic OLP who were confirmed of the disease histopathologically ( Fig. 3) were selected for the study. Patients with known history of hypersensitivity to tacrolimus and triamcinolone acetonide, suffering from diabetes mellitus and hypertension and patients on systemic steroid therapy were excluded from the study. Institutional ethical committee approval and informed consent from patients were obtained before the trial started. Patients were randomly divided into two groups. Study group comprised of 30 patients received topical tacrolimus 0.1% in orabase therapy for 14 days. Control group comprised of 30 patients received topical triamcinolone acetonide 0.1% in orabase for 14 days. After day 14 no treatment was given but called for clinical evaluation of lesion at the end of every week for 4 consecutive weeks. Their lesions were clinically graded by a 6-score scale 7 and their pain was assessed using the visual analog scale (VAS). The drug tacrolimus is not available in orabase in India. Hence, tacrolimus powder from Glenmark Pharmaceuticals Ltd, Mumbai, was added to the orabase and the concentration of 0.1% was obtained following the procedure described below.
The procedure was carried out using a vertical flow laminar hood. A total of 250 mg of tacrolimus powder was weighed and slowly added to 100 gm of previously weighed orabase until the mixture was uniform and dispensed in a sterile plastic container. Each patient in group 1 was given 15 gm units of the drug. Patients in group 2 were prescribed commercially available 0.1% triamcinolone acetonide (Kenacort ® 0.1% orabase manufactured by Piramal Life Science). The patients were advised to apply the prescribed drug regularly three times a day after food for 2 weeks. They were instructed to apply the drug with finger rub application on dried lesions and to abstain from food and liquid for 30 minutes after the application. Recall checkups were made at the end of every week for 4 consecutive weeks. During every clinical evaluation, the symptoms associated with the lesions were graded on a VAS with the severity of symptoms extending from the numerical '0' (no pain or discomfort) to 10 (severe most pain/discomfort). The clinical scoring of the lesions for the size and degree of erythema was done as per the criteria described by Thongaprassom et al. Clinical scores were graded as complete, partial or no response.
Statistical Analysis
Efficacy of the drug in both the groups was evaluated by Student's t-test/Mann-Whitney U-test by comparing the baseline scores to that obtained at the end of every week for 4 consecutive weeks. Intergroup comparison from baseline scores to that obtained at the end of every week for 4 consecutive weeks was done by Student paired t-test/ Wilson-Wilcoxon matched paired test, p-values < 0.05 were considered statistically significant.
RESULTS
Demographics in both the groups were showed in (Table 1) . On clinical examination of both the groups, it was observed that the most frequent site of involvement was the buccal mucosa ( Fig. 1A) bilaterally followed by tongue, gingiva, vestibule or palate ( Fig. 2A) . Five patients had more than two sites of involvement.
Twenty-nine of the 30 patients in study group (96%) and 27 of the 30 patients in control group (90%), had symptoms improvement after 4 weeks of treatment. However, one patient showed very mild improvement (VAS score of 10 before the start of treatment and eight after the end of treatment) and one patient had no improvement in the VAS score in study group (Table 2 ). Statistically significant difference was seen between study and control group when VAS was compared at the end of 21st and 28th day (p = 0.0309, 0.0001).
Similarly, twenty-eight of the 30 patients in study group (93%), while 16 of the 30 patients in control group (53%) showed clinical improvement after 4 weeks of treatment (Table 3) . We calculated the clinical improvement as the clinical score at the baseline to end of treatment (3.1 ± 0.8 for the study group and 2.7 ± 1.5 for the control group). Statistically significant difference was seen between study and control group when clinical scores were compared at the end of 28th day (p = 0.0030).
Clinical scores for LP (which indicates area of erythema, ulceration and white striation) are concerned 74.4%; reduction was seen in our study from baseline to 4 weeks of tacrolimus therapy (Figs 1B and 2B) . In control group, 45.1% reduction was seen in the clinical scores from baseline to 4 weeks. Statistically significant difference was seen between study and control group (p = 0.002). The greatest reduction of clinical scores was seen at the 4th week of follow-up (Table 4) .
Similarly both groups were showed statistically significant when intraobserver variation among VAS and clinical scores were compared from baseline to the end of 28th day (Table 5) .
There were no dropouts in the study and none of the patients reported any adverse effects. The swab cultures taken at 2nd and 4th week did not show growth of opportunistic fungal organisms.
DISCUSSION
The most commonly employed and useful agents for the treatment of LP are topical corticosteroids. 2, 8 Patients who demonstrate desquamative gingivitis, widespread oral disease or diffuse ulcerations, may not respond effectively to topical corticosteroids alone. The addition of potent immunosuppressant or immunomodulatory agents such as cyclosporine, tacrolimus, pimecrolimus or tretinoin, in topical formulations, is beneficial in this group of patients. 2, 3, 8 This study is the first clinical trial in India which aimed at evaluating the effectiveness and compliance of the administration of 0.1% topical tacrolimus in orabase for treatment of symptomatic OLP. In our study the number of male patients was marginally more compared to female patients. The male to female ratio in the study group was 1.3:1 and in the control group was 2:1 and is contrary to other studies which have higher number of female patients. 5, 9 On comparison of both the groups with respect to the VAS values, no statistical differences were found at the baseline, 7th and 14th day of treatment. But, there was a statistically significant difference in VAS scores between the two groups on the 21st day (p = 0.0309) and 28th day (p = 0.0001) of the treatment. Similar study was done by author but they have not assessed the VAS scores. 10 Both study and control groups showed complete reduction in degree of erythema from baseline to end of 4th week (95.811 and 68.5% respectively). The results were statistically significant in both the groups with p-values of 0.0000 and 0.0001 respectively. Obviously no statistical difference was observed when the intergroup comparison was done (p = 0.7007). This result was compared to other studies 11 which shows statistically significant reduction in study group compared to placebo. In the present study, patients in two groups showed complete reduction in mean surface area of ulceration from baseline to end of 4th week (100 and 95.8% respectively). The results were statistically significant with p-values of 0.0117 and 0.0277 respectively. Kaliakatosu et al also found a statistically significant reduction (73.3%) in mean area of ulceration seen over the 8 weeks of study period. 7 In our study 92% (24.33-1.94) reduction of white striation in study group and 80.61% (25.18-4.88) reduction in control group were seen between baseline to 28th day follow-up. Statistically significant difference was seen between two groups (p < 0.05). Patients on tacrolimus had responded better than the patients on triamcinolone acetonide. Harpenau et al in their study found 60% reduction of white striation in study group and 94.7% in control group from baseline to 4 weeks of treatment.
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As far as clinical scores for LP (which indicates area of erythema, ulceration and white striation) are concerned 74.4% reduction was seen in our study from baseline to 4 weeks of tacrolimus therapy. In control group 45.1% reduction was seen in the clinical scores from baseline to 4 weeks. Statistically significant difference was seen between study and control group (p = 0.002). The greatest reduction of clinical scores was seen at the 4th week. Similarly Kaliakatosu et al in their study found that all 17 patients had a significant reduction in their clinical scores from baseline to 8 weeks of tacrolimus therapy and 73.3% reduction in the mean surface area of LP lesion (p < 0.002). 7 During follow-up evaluation 40% of patients in the study group revealed melanin pigmentation at the site of the lesion indicating the healing phase of LP. Maximum incidence of pigmentation was seen in patients with erosive LP. The fact is substantiated by increased melanocytic activity at the basement membrane during the healing and posthealing phase.
In our study, none of the patients had reported adverse effects during and after application of drug tacrolimus except pigmentation which would indicates the healing phase of OLP. The absence of any severe side effects, specifically 'burning' at the site of application may be attributed to the fact that we did not use tacrolimus in other vehicular bases. Studies reported that one-third of the patients complained of adverse effects at the site of application. [12] [13] [14] [15] Patients in 
CONCLUSION
This study suggests that tacrolimus is more efficient in the management of oral LP than triamcinolone acetonide. There were no clinically noticeable side effects observed with tacrolimus. However, its long-term effects are yet to be known. Hence, tacrolimus can be considered as a good alternative topical medication in the treatment of oral LP especially in those patients who do not respond to topical corticosteroids.
